Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer

World Journal of Gastroenterology

Volumn 10, Issue 18, 2004, Pages 2750-2752

  Yue, Shu Qiang ^a   Yang, Yan Ling ^a   Zhou, Jing Shi ^a   Li, Kai Zong ^a   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR; VASCULOTROPIN;

ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; GALLBLADDER CANCER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PHENOTYPE; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 4544364992     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i18.2750     Document Type: Article

References (40)

1. Braun S, Harbeck N. Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention. Expert Rev Mol Med 2001; 6: 1-14
2. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003; 9: 193-200
3. Quaranta V, Giannelli G. Cancer invasion: watch your neighbourhood. Tumori 2003; 89: 343-348
4. Townson JL, Naumov GN, Chambers AF. The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003; 3: 631-642
5. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, Magdolen V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9: 1529-1543
6. Cunningham O, Andolfo A, Santovito ML, Iuzzolino L, Blasi F, Sidenius N. Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J 2003; 22: 5994-6003
7. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara. M, Nakao K, Nakamura M, Mori I, Kakudo K. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 2003; 9: 5313-5317
8. Jiang CQ, Liu ZS, Qian Q, He YM, Yuan YF, Ai ZL. Relationship of Hypoxia-Inducible Factor 1 Alpha (HIF-1alpha) Gene Expression with Vascular Endothelial Growth Factor (VEGF) and Microvessel Density (MVD) in Human Colorectal Adenoma and Adenocarcinoma. Aizheng 2003; 22: 1170-1174
9. Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002; 2: 135-156
10. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, Raddatz D, Emons G, Hofbauer LC. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003; 88: 4206-4213
11. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 2003; 89: 983-991
12. Michael-Robinson JM, Pandeya N, Cummings MC, Wakh MD, Young JP, Leggett BA, Purdie DM, Jass JR, Radford-Smith GL. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. J Pathol 2003; 201: 46-54
13. Machner A, Baier A, Wille A, Drynda S, Pap G, Drynda A, Mawrin C, Buhling F, Gay S, Neumann W, Pap T. Higher susceptibility to Fas ligand induced apoptosis and altered modulation of cell death by tumor necrosis factor-alpha in periarticular tenocytes from patients with knee joint osteoarthritis. Arthritis Res Ther 2003; 5: 253-261
14. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40
15. Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Janicke F, Pantel K. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 2003; 107: 903-909
16. Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med 2000; 38: 679-692
17. Van Hensbergen Y, Broxterman HJ, Peters E, Rana S, Elderkamp YW, Van Hinsbergh VW, Koolwijk P. Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix. Thromb Haemost 2003; 90: 921-929
18. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001; 21: 146-170
19. Ramont L, Pasco S, Hornebeck W, Maquart FX, Monboisse JC. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. Exp Cell Res 2003; 291: 1-10
20. De Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24: 13-39
21. Le Gat L, Gogat K, Bouquet C, Saint-Geniez M, Darland D, Van Den Berghe L, Marchant D, Provost A, Perricaudet M, Menasche M, Abitbol M. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther 2003; 10: 2098-2103
22. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL, Gibbs JF. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003; 9: 4935-4943
23. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001; 10: 393-415
24. Mabrouk RA, Ali-Labib R. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma. Clin Biochem 2003; 36: 537-543
25. Hamdi HK, Castellon R. ACE inhibition actively promotes cell survival by altering gene expression. Biochem Biophys Res Commun 2003; 310: 1227-1235
26. Shin YC, Folk WR. Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor. J Virol 2003; 77: 11491-11498
27. Zhang F, Tom CC, Kugler MC, Ching TT, Kreidberg JA, Wei Y, Chapman HA. Distinct tigand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J Cell Biol 2003; 163: 177-188
28. Leung YK, Ng TB, Ho JW. Transcriptional regulation of fosl-1 by licorice in rat Clone 9 cells. Life Sci 2003; 73: 3109-3121
29. Lloyd FP Jr, Slivova V, Valachovicova T, Sliva D. Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol 2003; 23: 1277-1283
30. Roelofs JJ, Rowshani AT, van den Berg JG, Claessen N, Aten J, ten Berge IJ, Weening JJ, Florquin S. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kidney Int 2003; 64: 1845-1853
31. Baker EA, Bergin FG, Leaper DJ. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 2000; 53: 307-312
32. Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, Kamiya K, Tanaka T, Suzuki S, Nakamura S, Urano T. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 2001; 92: 516-523
33. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades N. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88: 5392-5398
34. Koide N, Nishio A, Kono T, Hiraguri M, Watanabe H, Igarashi J, Hanazaki K, Adachi W, Amano J. Histochemical study of angiogenesis in basaloid squamous carcinoma of the esophagus. Dis Esophagus 2000; 13: 142-147
35. Koshida K, Konaka H, Kato H, Miyagi T, Egawa M, Uchibayashi T, Namiki M. Correlation between expression of metastasis-related genes and lymph node metastasis in testicular cancer. Hinyokika Kiyo 2000; 46: 775-781
36. Oh CW, Hoover-Plow J, Plow E. The role of plasminogen in angiogenesis in vivo. J Thromb Haemost 2003; 1: 1683-1687
37. Dazzi C, Cariello A, Maioli P, Magi S, Rosti G, Giovanis P, Giovannini G, Lanzanova G, Marangolo M. A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. Cancer Invest 2003; 21: 208-216
38. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003; 94: 43-49
39. Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu MY, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, Rao JS, Baker AH, Bennet JT, Crombleholme TM, Velazquez O, Karmacharya J, Margolis DJ, Wilson JM, Detmar M, Skobe M, Robbins PD, Buck C, Herlyn M. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol 2003; 120: 683-692
40. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003; 17: 752-754